31 news items
Ocugen Announces CSO to Present on Modifier Gene Therapy at International Society for Cell & Gene Therapy 2024
OCGN
20 May 24
the Company's 2026 BLA and MAA approval targets. OCU400 is the first gene therapy program to enter Phase 3 with a broad RP indication
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against HireRight, Checkpoint, Ocugen, and Sonder Innovations and Encourages Investors to Contact the Firm
CKPT
HRT
OCGN
16 May 24
, 2024 Checkpoint is a clinical-stage immunotherapy and targeted oncology company that focuses on the acquisition
Chardan Capital Maintains Buy on Ocugen, Maintains $5 Price Target
OCGN
15 May 24
Chardan Capital analyst Daniil Gataulin maintains Ocugen (NASDAQ:OCGN) with a Buy and maintains $5 price target.
4 Analysts Assess Ocugen: What You Need To Know
OCGN
15 May 24
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $6.5, along
HC Wainwright & Co. Reiterates Buy on Ocugen, Maintains $7 Price Target
OCGN
15 May 24
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Ocugen (NASDAQ:OCGN) with a Buy and maintains $7 price target.
9edx0u4 98e7lsux37sie7b07p5uoqzj0
CKPT
HRT
OCGN
12 May 24
is a clinical-stage immunotherapy and targeted oncology company that focuses on the acquisition, development, and commercialization of novel
pbdq7zhokk6uqnm7fcov zmwci6agh3amr3dpgl9j
CKPT
HRT
OCGN
7 May 24
Checkpoint is a clinical-stage immunotherapy and targeted oncology company that focuses on the acquisition, development, and commercialization of novel
szdf3lvxkw r1ll8h4ke62d0ug1m
OCGN
2 May 24
and on track to meet the Company's 2026 BLA and MAA approval targets. OCU400 is the first gene therapy program to enter Phase 3 with a broad retinitis
454aic6swbiz7l548olpcfzhrpdusw5cu22qtl9g25obb2igi
DD
DYAI
HCA
29 Apr 24
.
On April 5, 2023, Ladenburg Thalmann set a target price of $4, see
aksu7py25renoxua7m8cwb598na i5xwfs5nbbl6
ADXN
ALT
ALTM
29 Apr 24
and maintained a $4 price target.
Cyclacel Pharmaceuticals, Inc
v2sgchurjoygmdg85arz5rf62umtdn8q y3objma4c26h8rzo70hbaky
OCGN
29 Apr 24
trial is currently underway and on track to meet the Company's 2026 BLA and MAA approval targets. Between the U.S. and EU, nearly 300,000 people
343z2djvoxq0jvccvlc286
OCGN
26 Apr 24
filing targets. About AAV-hRORA (OCU410/OCU410ST) AAV
midqd4 wmnm703342kj
AA
ACCD
BYND
22 Apr 24
and downgrades, please see our analyst ratings page.
Susquehanna raised the price target
xwh6rgvtudy09tzugtb4bgh2ruxhsrcqcqxriqi3kiruuo
OCGN
19 Apr 24
therapies for GA targeting a single pathway of the disease, which has multifactorial and complex etiology," said Syed M. Shah, MD, Vice Chair of Research
bbm49fo xjge32bmbgyp
CC
OCGN
15 Apr 24
to additional cash compensation if certain targets, including Free Cash Flow targets, were met. Similarly, pursuant to Chemours's Long-Term Incentive Plans
4s6amoob61
OCGN
10 Apr 24
. With this milestone, OCU400 remains on track for 2026 BLA and MAA approval targets. About OCU400OCU400
xmfut4r93ie mgw
OCGN
8 Apr 24
across various disease stages.
With orphan drug and RMAT designations already secured, Ocugen targets BLA approval for OCU400 by 2026
xitoyh3wkji4c62rto9nhnyfvbdd9ai4 w2134tkmtjxy7
OCGN
8 Apr 24
remains on track for the 2026 BLA approval target. About OCU400OCU400 is the Company's
5rs7v um0jr5vrw3nk8ix7uyyh8bj
OCGN
5 Apr 24
have significant limitations, as they require multiple injections per year and only target one pathway contributing to GA. OCU410 regulates multiple
m5hjwjiwuqu82unra160s8clje0mbwv cda2f8vlwbxm
OCGN
3 Apr 24
delivery.
Additionally, enrollment and dosing progress were noted in OCU410 and OCU410ST trials targeting conditions like dry Age-Related Macular